The Newsroom

Investigations  /  05.06.2021

Investigation of LifeMD, Inc.

LifeMD, Inc. (LFMD) Misled Investors Regarding its Business Operations Throughout the class period, defendants made ...

READ MORE
Investigations  /  05.05.2021

Investigation of GoodRX Holdings, Inc.

GoodRx Holdings, Inc. (GDRX) Misled Shareholders Regarding its Business Prospects      Defendants timed the Company's ...

READ MORE
Investigations  /  05.04.2021

Investigation of Lordstown Motors Corp.

Lordstown Motor Corporation (RIDE) Misled Investors About its Endurance Orders and Production Capabilities On August ...

READ MORE
Investigations  /  05.03.2021

Investigation of 3D Systems Corp.

3D Systems Corp. (DDD) Lacked Proper Internal Controls Over Financial Reporting   Throughout the class ...

READ MORE
Investigations  /  05.03.2021

Investigation of Lordstown Motors Corp.

Lordstown Motor Corporation (RIDE) Misled Investors About its Endurance Orders and Production Capabilities On August ...

READ MORE
Investigations  /  04.30.2021

Investigation of Peloton Interactive, Inc.

Peloton Interactive Inc. (PTON) Misled Investors Regarding the Company's Concerns for User Safety In October ...

READ MORE
Investigations  /  04.30.2021

Investigation of 3D Systems Corp.

3D Systems Corp. (DDD) Lacked Proper Internal Controls Over Financial Reporting   Throughout the class ...

READ MORE
Investigations  /  04.23.2021

Investigation of Clover Health Investments

Clover Health Investment, Corp.  (CLOV) Misled Shareholders Ahead of Going Public            On October 6, ...

READ MORE
Investigations  /  04.23.2021

Investigation of Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. (ACAD) Misled Shareholders Regarding the Viability of Pimavanserin for Dementia-Related Psychosis       ...

READ MORE
Investigations  /  04.23.2021

Investigation of Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (EBS) Misled Investors Regarding its Business Operations In response to the COVID-19 ...

READ MORE


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns